In the last trading session, 3.78 million Humacyte Inc (NASDAQ:HUMA) shares changed hands as the company’s beta touched 1.65. With the company’s per share price at $1.35 changed hands at -$0.1 or -6.90% during last session, the market valuation stood at $209.41M. HUMA’s last price was a discount, traded about -638.52% off its 52-week high of $9.97. The share price had its 52-week low at $1.30, which suggests the last value was 3.7% up since then. When we look at Humacyte Inc’s average trading volume, we note the 10-day average is 9.18 million shares, with the 3-month average coming to 3.29 million.
Analysts gave the Humacyte Inc (HUMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended HUMA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Humacyte Inc’s EPS for the current quarter is expected to be -0.21.
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA was in red as seen at the end of in last trading. With action -31.12%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -73.27%, with the 5-day performance at -31.12% in the red. However, in the 30-day time frame, Humacyte Inc (NASDAQ:HUMA) is -54.39% down. Looking at the short shares, we see there were 26.6 million shares sold at short interest cover period of 11.69 days.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 83.12% from its current market value. According to analyst projections, HUMA’s forecast low is 6 with 10 as the target high. To hit the forecast high, the stock’s price needs a -640.74% plunge from its current level, while the stock would need to soar -344.44% for it to hit the projected low.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 457.8k. 5 analysts are of the opinion that Humacyte Inc’s revenue for the current quarter will be 1.17M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 42.43%. The 2025 estimates are for Humacyte Inc earnings to increase by 39.23%.
HUMA Dividends
Humacyte Inc is expected to release its next quarterly earnings report on 2025-Mar-27.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 21.25% of Humacyte Inc shares while 27.45% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 34.85%. There are 27.45% institutions holding the Humacyte Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.9912% of the shares, roughly 7.14 million HUMA shares worth $34.27 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . With 2.59 shares estimated at $3.5 million under it, the former controlled 1.79% of total outstanding shares. On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF held about 1.69% of the shares, roughly 2.45 shares worth around $3.31 million.
